Accord Healthcare Ltd.

Henlius' Serplulimab Makes History as First PD-1 Inhibitor Approved in EU for Small Cell Lung Cancer

- Shanghai Henlius Biotech's serplulimab (Hetronifly) receives European Commission approval as the first anti-PD-1 antibody for extensive-stage small cell lung cancer treatment. - The approval is based on the ASTRUM-005 trial involving 585 patients across multiple countries, demonstrating significant efficacy in combination with carboplatin and etoposide. - The drug has already benefited over 90,000 patients across China, Europe, and Southeast Asia, with Henlius maintaining 48,000-liter manufacturing capacity to ensure consistent global supply.